Stephen Stranks

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Relative Hyperglycemia, a Marker of Critical Illness: Introducing the Stress Hyperglycemia Ratio

G.W. Roberts, Stephen Quinn, Nyoli Valentine et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 577 citations · Full text

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Stephen Stranks et al. · The Lancet · 2010 · 435 citations

Diabetes Management, Insulin Glargine, Insulin Management +9

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD

Morton G. Burt, G.W. Roberts, Norma R. Aguilar-Loza et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 202 citations · Full text